Latest News from Lone Oak
August and November 2015 Trade Shows
Lone Oak Medical Technologies will be exhibiting at the following trade shows: FIME Show, Miami Fl August 5 - 7, 2015 MEDICA 2015 November 16 - 19, 2015 Dusseldorf, Germany
May 2015: accudxa2 authorized in Canada
HEALTH CANADA has authorized Lone Oak Medical Technologies LLC to begin marketing the accudxa2® in Canada. This is especially important to Lone Oak Medical because Pharmacies in Canada can perform many sophisticated test on patients because of the Canadian Health organization emphasis on preventive care.
April 2015: ALFA Conference May 5-6, 2015
The ALFA Conference was a success with lots of attendees stopping by to get their free accudxa2 screening. There were many discussions on how the accudxa2 will help facilities meet their HIDE requirements for Osteoporosis detection.
Lone Oak Medical Technologies will be exhibiting at the ALFA 2015 Conference on May 5-6, 2015. Attendees can visit Booth 349 to receive a free bone density screening on the accudxa2®. The Assisted Living Federation of America (ALFA) is the largest national association exclusively dedicated to senior living communities and the seniors and families they serve.
Mar 2015: Lone Oak Publishes Suggested Diagnostic T-Score Cutoff Level Study
View Press Release
Feb 2015: Recent Presentation at the International Society for Clinical Densitometry
Preliminary results of the Lone Oak Medical Technologies' sponsored reliability study were presented at the February 2015 International Society for Clinical Densitometry annual scientific conference in Chicago, Illinois. The presentation "Pointing the Finger at Bone Density Screening: Part II" focused on preliminary findings of an accudxa2® reliability study in the Dominican Republic (February - December 2014). The study compared the results of the accudxa2® device (finger) to a central bone density testing device (hip, femur neck, lumbar spine, and forearm) of 375 participants. The overall study showed very good reliability of accudxa2®, consistent with previous studies. Further statistical analyses of determining concordance between accudxa2® and the central device (determining if the accudxa2® results are consistent in categorizing "Osteoporosis" "Low Bone Density" "Normal") were also determined to be clinically relevant. Further analyses are now being conducted. Lone Oak Medical Technologies is committed to quality assurance and will use these results as part of its mission focus on "the first line defense against osteoporosis."
News Release Jan 2015
Research findings to be presented at the International Society for Clinical Densitometry annual meeting! Our most recent study was conducted in the Dominican Republic and tested the reliability of the accudxa2® device in predicting osteoporosis, compared to central dual energy x-ray absorptiometry (DXA). Nearly 400 adults participated, with preliminary results indicating high reliability of accudxa2® in determining osteoporosis. The poster entitled "Pointing the Finger at Bone Density Screening: Part II" will present preliminary results at the annual meeting of the International Society for Clinical Densitometry on February 26th - 28th, 2015 at The Palmer House in Chicago, Illinois. Because of the importance of this study, you will find us at Booth #1.
Lone Oak Medical Technologies' Ongoing Research to Improve Screening Reliability
Lone Oak Medical Technologies continues to promote studies that compare the diagnostic accuracy of their peripheral Dual Energy X-ray Absorptiometry (DXA) bone densitometer with results from a central DXA exam of the femur neck. We feel that this is another example of why there should be more screening of patients under the age of 50 so they can do something about their life style to improve their BMD Bone mineral density at one anatomical site (for example the hip) is not necessarily the same as at another site. No two sites agree diagnostically in all tests. Nevertheless, many studies have demonstrated clinically useful diagnostic agreement between peripheral and central skeletal sites, and have also demonstrated the clinical utility of peripheral D)(A measurements in fracture risk assessment. To determine how well the accudxa2® diagnosis at the finger agreed with diagnoses derived from central skeletal sites, Lone Oak Medical Technologies and Winona State University conducted a reliability study (n=66) assessing the finger, hip, femoral neck, lumbar spine and forearm using an accudxa2® and a Hologic central DXA unit. Compared to the Hologic central DXA unit measuring the femoral neck, the accudxa2® showed overall agreement accuracy of 77% using Lone Oak Medical Technologies' suggested T-score cutoff values of +0.2SD for Low BMD and -2.25D for osteoporosis. Accuracy at the osteoporosis cutoff level was 95%. Using preliminary software changes made as a result of the findings of the study, Lone Oak Medical Technologies improved the overall agreement accuracy of the machine to 89% for Caucasian post-menopausal women by refining the region of interest to an area of the finger where the bone structure more closely resembles that of the femoral neck. Accuracy at the osteoporosis cutoff level was 98%. A second much larger study (n=500) is now under way in the Dominican Republic under the guidance of Dr Juan Carlos Vargas, ISCD CCD, CDT and Professor of Endocrinology at Universidad lberoamericana (UNIBE) to validate the findings from the first reliability study. Lone Oak Medical Technologies proposes to use the findings from the Dominican Republic Reliability Study to drive enhancements to the accudxa2® in areas such as a focused region of interest, more flexibility in using alternative diagnostic cutoff levels, and inclusion of other fracture risk assessment risk factors in the screening process. It is generally accepted that about 65% of postmenopausal women are not tested for bone density disorders. We strongly believe that unless more peripheral exams are performed, this statistic will never change.